4D Molecular Therapeutics Inc
FDMT5.288USD
-1.132-17.63%
Horarios del mercado （ET）Cotizaciones retrasadas 15 min
244.97MCap. mercado
PérdidaP/E TTM
Más Datos de 4D Molecular Therapeutics Inc Compañía
4D Molecular Therapeutics, Inc. is a clinical-stage genetic medicines company focused on unlocking the full potential of genetic medicines to treat diseases in ophthalmology and pulmonology. The Company has a portfolio of genetic medicine product candidates, with five product candidates in clinical trials in seven patient populations: 4D-150 for the treatment of wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME), 4D-710 for the treatment of cystic fibrosis lung disease (both in modulator ineligible and eligible populations), 4D-310 for the treatment of Fabry disease cardiomyopathy, 4D-125 for the treatment of X-linked retinitis pigmentosa (XLRP), and 4D-110 for the treatment of choroideremia. In addition, it has two product candidates in preclinical development: 4D-175 for geographic atrophy (GA) and 4D-725 for alpha-1 antitrypsin deficiency lung disease.
Información de la empresa
Símbolo de cotizaciónFDMT
Nombre de la empresa4D Molecular Therapeutics Inc
Fecha de salida a bolsaDec 11, 2020
Director ejecutivoDr. David Kirn, M.D.
Número de empleados227
Tipo de seguridadOrdinary Share
Fin del año fiscalDec 11
Dirección5858 Horton Street #455
CiudadEMERYVILLE
Bolsa de valoresNASDAQ Global Select Consolidated
PaísUnited States of America
Código postal94608
Teléfono15105052680
Sitio Webhttps://4dmoleculartherapeutics.com/
Símbolo de cotizaciónFDMT
Fecha de salida a bolsaDec 11, 2020
Director ejecutivoDr. David Kirn, M.D.
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. David Kirn, M.D.
Dr. David Kirn, M.D.
Chief Executive Officer, Co-Founder, Director
Chief Executive Officer, Co-Founder, Director
1.66M
-0.02%
Dr. John F. Milligan, Ph.D.
Dr. John F. Milligan, Ph.D.
Executive Chairman of the Board
Executive Chairman of the Board
100.00K
--
Dr. Fariborz (Fred) Kamal, Ph.D.
Dr. Fariborz (Fred) Kamal, Ph.D.
President, Chief Operating Officer
President, Chief Operating Officer
5.94K
--
Dr. Scott Bizily, J.D., Ph.D.
Dr. Scott Bizily, J.D., Ph.D.
Chief Legal Officer and Corporate Secretary
Chief Legal Officer and Corporate Secretary
--
--
Dr. Dhaval Desai, Pharm.D.
Dr. Dhaval Desai, Pharm.D.
Chief Development Officer
Chief Development Officer
--
--
Dr. Charles P. Theuer, M.D., Ph.D.
Dr. Charles P. Theuer, M.D., Ph.D.
Independent Director
Independent Director
--
--
Ms. Nancy Miller-Rich
Ms. Nancy Miller-Rich
Independent Director
Independent Director
--
--
Dr. Jacob M. Chacko, M.D.
Dr. Jacob M. Chacko, M.D.
Independent Director
Independent Director
--
--
Mr. Christopher (Chris) Simms
Mr. Christopher (Chris) Simms
Chief Commercial Officer
Chief Commercial Officer
--
--
Dr. Robert (Bob) Kim, M.D.
Dr. Robert (Bob) Kim, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. David Kirn, M.D.
Dr. David Kirn, M.D.
Chief Executive Officer, Co-Founder, Director
Chief Executive Officer, Co-Founder, Director
1.66M
-0.02%
Dr. John F. Milligan, Ph.D.
Dr. John F. Milligan, Ph.D.
Executive Chairman of the Board
Executive Chairman of the Board
100.00K
--
Dr. Fariborz (Fred) Kamal, Ph.D.
Dr. Fariborz (Fred) Kamal, Ph.D.
President, Chief Operating Officer
President, Chief Operating Officer
5.94K
--
Dr. Scott Bizily, J.D., Ph.D.
Dr. Scott Bizily, J.D., Ph.D.
Chief Legal Officer and Corporate Secretary
Chief Legal Officer and Corporate Secretary
--
--
Dr. Dhaval Desai, Pharm.D.
Dr. Dhaval Desai, Pharm.D.
Chief Development Officer
Chief Development Officer
--
--
Dr. Charles P. Theuer, M.D., Ph.D.
Dr. Charles P. Theuer, M.D., Ph.D.
Independent Director
Independent Director
--
--
Desglose de ingresos
Divisa: USDActualizado: dom., 6 de jul
Divisa: USDActualizado: dom., 6 de jul
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
Sin datos
Por regiónUSD
Nombre
Ganancia
Proporción
United States
14.00K
0.00%
Netherlands
0.00
0.00%
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: sáb., 17 de may
Actualizado: sáb., 17 de may
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
RA Capital Management, LP
9.85%
BVF Partners L.P.
9.85%
Goldman Sachs & Company, Inc.
8.09%
BlackRock Institutional Trust Company, N.A.
7.63%
The Vanguard Group, Inc.
5.95%
Other
58.64%
Accionistas
Accionistas
Proporción
RA Capital Management, LP
9.85%
BVF Partners L.P.
9.85%
Goldman Sachs & Company, Inc.
8.09%
BlackRock Institutional Trust Company, N.A.
7.63%
The Vanguard Group, Inc.
5.95%
Other
58.64%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor/Hedge Fund
23.29%
Investment Advisor
21.67%
Hedge Fund
17.81%
Venture Capital
16.25%
Research Firm
14.94%
Individual Investor
3.88%
Sovereign Wealth Fund
1.08%
Pension Fund
1.01%
Bank and Trust
0.10%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
351
46.53M
100.45%
-12.51M
2025Q1
358
46.38M
99.71%
-13.16M
2024Q4
357
49.60M
107.13%
-13.93M
2024Q3
350
60.77M
117.85%
-4.39M
2024Q2
340
60.30M
117.01%
-2.54M
2024Q1
324
59.47M
116.84%
+10.27M
2023Q4
284
45.54M
106.82%
-1.53M
2023Q3
275
45.63M
108.12%
-4.94M
2023Q2
263
44.82M
109.79%
-393.70K
2023Q1
254
34.42M
103.72%
-2.13M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
RA Capital Management, LP
4.56M
9.85%
--
--
Mar 31, 2025
BVF Partners L.P.
4.56M
9.85%
+1.89M
+70.79%
Mar 31, 2025
Goldman Sachs & Company, Inc.
3.75M
8.09%
-81.59K
-2.13%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
3.53M
7.63%
-321.37K
-8.34%
Mar 31, 2025
The Vanguard Group, Inc.
2.76M
5.95%
-97.19K
-3.40%
Mar 31, 2025
Novo Holdings A/S
1.95M
4.21%
+450.00K
+30.00%
Mar 31, 2025
Janus Henderson Investors
1.89M
4.08%
-360.31K
-16.00%
Mar 31, 2025
Kirn (David)
1.66M
3.58%
-360.00
-0.02%
Apr 24, 2025
Millennium Management LLC
1.63M
3.53%
+213.26K
+15.01%
Mar 31, 2025
Morgan Stanley & Co. LLC
1.29M
2.78%
-316.21K
-19.71%
Mar 31, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 2 de ago
Actualizado: sáb., 2 de ago
Nombre
Proporción
Federated Hermes MDT Small Cap Core ETF
0.32%
Harbor Human Capital Factor US Small Cap ETF
0.08%
iShares Micro-Cap ETF
0.03%
ProShares Ultra Nasdaq Biotechnology
0.02%
Invesco Nasdaq Biotechnology ETF
0.02%
iShares Biotechnology ETF
0.02%
iShares Health Innovation Active ETF
0.02%
ProShares Hedge Replication ETF
0.01%
iShares Russell 2000 Value ETF
0.01%
Avantis US Small Cap Equity ETF
0.01%
Ver más
Federated Hermes MDT Small Cap Core ETF
Proporción0.32%
Harbor Human Capital Factor US Small Cap ETF
Proporción0.08%
iShares Micro-Cap ETF
Proporción0.03%
ProShares Ultra Nasdaq Biotechnology
Proporción0.02%
Invesco Nasdaq Biotechnology ETF
Proporción0.02%
iShares Biotechnology ETF
Proporción0.02%
iShares Health Innovation Active ETF
Proporción0.02%
ProShares Hedge Replication ETF
Proporción0.01%
iShares Russell 2000 Value ETF
Proporción0.01%
Avantis US Small Cap Equity ETF
Proporción0.01%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
